Acadia Pharmaceuticals 2025 Q3 Earnings Beats Estimates with 119.1% Net Income Growth

Acadia Pharmaceuticals (ACAD) reported fiscal 2025 Q3 earnings on Nov 6, 2025, exceeding expectations with a 11.3% revenue increase and a 119.1% surge in net income. The company raised its full-year revenue guidance, reflecting strong demand for its flagship products, NUPLAZID and DAYBUE, and a favorable tax environment.

Revenue

Driven by robust product sales, Acadia’s total revenue surged to $278.63 million, with net product sales contributing the entire amount. This represents a 11.3% year-over-year increase, fueled by 12% growth in NUPLAZID sales to $177.5 million and 11% growth in DAYBUE sales to $101.1 million. The expansion of field operations and international named patient programs further bolstered performance.

Earnings/Net Income

Acadia’s EPS jumped 115% to $0.43 in Q3 2025 from $0.20 in Q3 2024, while net income hit a record $71.78 million—a 119.1% increase. This marks the highest Q3 net income in over two decades, driven by higher sales and a one-time tax benefit. The EPS growth underscores the company’s profitability resilience.

Post-Earnings Price Action Review

The strategy of buying ACAD shares on revenue-raise announcements and holding for 30 days delivered a 24.5% cumulative return over three years, outperforming the S&P 500’s 6.5% average annual return. The stock closed at $22.33 on the day after the announcement, a 2.11% rise, signaling positive market sentiment. This approach highlights the value of capitalizing on short-term momentum post-earnings.

CEO Commentary

Catherine Owen Adams, CEO, credited record NUPLAZID and DAYBUE sales for the strong performance, emphasizing new prescriptions and expanded operations. She expressed confidence in achieving $1 billion in 2025 sales, driven by commercial growth and pipeline advancements like ACP-204 and trofinetide trials.

Guidance

Acadia updated 2025 revenue guidance to $1.07–$1.095 billion, with NUPLAZID net sales now projected at $685–$695 million and DAYBUE at $385–$400 million. R&D expenses are expected to range from $335–$345 million, while SG&A costs will stay within $540–$555 million. The revised guidance includes international contributions, reflecting broader market optimism.

Additional News

Recent developments include Catherine Owen Adams’ appointment as Chairperson of the BIO Emerging Companies section and the hiring of Konstantina Katcheves as Chief Business and Strategy Officer. The company also advanced its pipeline with Phase 2/3 trials for ACP-204 and trofinetide. These moves underscore strategic priorities to expand commercial reach and accelerate innovation in neurological and rare disease treatments.